Your AI-Trained Oncology Knowledge Connection!

Opinion

Video

Sequencing Therapies in the Third-Line and Beyond Setting for MCL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
SHAH
Timothy S. Fenske, MD, MS
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center
Tycel J. Phillips, MD, MPH
Daniel J. DeAngelo, MD, PhD, chief of the Division of Leukemia and an institute physician at Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School
Julie M. Vose, MD, MBA
Martin Dreyling, MD
Alberto Chiappori, MD
Marco Davila, MD, PhD, the senior vice president and associate director for Translational Research in the Department of Medicine, as well as the Rustum Family Endowed Chair in Translational Research at Roswell Park Comprehensive Cancer Center
Related Content
New Immunotherapy Strategy for Enhancing Melanoma Treatment | Image Credit: Maris– stock.adobe.com
March 24th 2025

Moffitt Study Finds New Immunotherapy Strategy for Enhancing Melanoma Treatment

Roxana S. Dronca, MD, professor, oncology, consultant, Division of Hematology/Oncology, Department of Internal Medicine, director, Mayo Clinic Comprehensive Cancer Center
January 20th 2025

FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

Physical Functioning Measures With CAR T-Cell Therapy in NHL | Image Credit: © LASZLO– stock.adobe.com
March 23rd 2025

Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

R/R DLBCL | Image Credit: © LASZLO - stock.adobe.com
March 20th 2025

FDA Grants Fast Track Designation to Azer-Cel for R/R DLBCL

Monica Chatwal, MD, a medical oncologist at Moffitt Cancer Center in Tampa, Florida
March 20th 2025

PARP Inhibitor and ARPI Combinations Are at the Forefront of Investigations in mCRPC